Medicine has long aimed to deliver the most good for the most people. Emerging technologies such as low-cost genetic sequencing, AI and CRISPR cas-9 allow us to shift from this collectivist model to a personalized one. In this provocative panel, we will explore the past, current and future of personalized medicine from risk identification and early intervention to targeted therapies that leverage genetic outliers. Find out how the personalized medicine revolution impacts patient experience and clinical workflow, and shifts the core philosophies of medical protocol.


Dan Seewald, Founder and CEO at Deliberate Innovation and designer of the Deliberate Innovation System™, which combines design thinking and creative problem solving methods with high-performance coaching. Dan is also the Former Head of Pfizer’s World Wide Innovation group where he designed and led the Dare to Try program, one of the Fortune 100’s leading design thinking and strategic innovation programs. Dan is a recognized speaker and author in the field of applied creativity and corporate innovation and regularly contributes for multiple journals, including: Innovation Leader and People Science.

With special guests:

Olivier Elemento, PhD., Director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine. He is also Associate Director of the Institute for Computational Medicine and Associate Program Director of the Clinical Translational Science Center. His group combines Big Data with experimentation and genomic profiling to accelerate the discovery of cancer cures and prevention strategies. His lab developed AI-driven methodologies to repurpose existing drugs to target specific pathways, predict drug toxicity and identify synergistic drug combinations. He has also developed augmented reality approaches for visualizing complex biomedical information. He is co-founder of two
investor-funded startups: Volastra Therapeutics and One Three Biotech.

Tammi Jantzen, Co-founder and CFO at Astarte Medical, a precision medicine company using software and predictive analytics to improve outcomes for preterm infants in the neonatal ICU with a suite of digital tools and diagnostics designed to standardize feeding, optimize nutrition and quantify gut health.  Prior to Astarte Medical, Tammi spent 15 years in venture capital. She is a certified public accountant and an honored member of the Kauffman Fellows Society.

Adlai Goldberg,EY Global Life Sciences Digital, Social and Commercial Innovation Leader. In his role, Adlai is focused on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases.

Codi Amir Gharagouzloo, PhD, Founder and CEO of Imaginostics, a Boston based health tech startup developing breakthrough magnetic resonance imaging (MRI) biomarkers. The company’s QUTE-CE MRI software suite works with existing MRI scanners and can be used to stratify patient populations, provide early diagnosis of complex diseases, and assess drug efficacy in clinical trials. Dr. Gharagouzloo invented the Quantitative Ultra-short Time-to-echo Contrast-Enhanced (QUTE-CE) MRI method while completing his Ph.D. in Bioengineering at Northeastern University. He furthered his research during a postdoctoral fellowship at the Gordon Center for Medical Imaging at Massachusetts General Hospital and Harvard Medical School. Ultimately, Dr. Gharagouzloo would like to help patients age gracefully by giving them a prognosis years in advance of disease onset.

6:30 PM Doors Open
7:00 PM Program Begins
Light bites and drinks to follow